Threats to Science-Based Medicine: When Clinical Trials for New Drugs Are Designed by the Marketing Division

Science-based medicine is supposed to be gloriously boring in the best possible way. A good clinical trial asks a plain question, uses a fair comparison, measures outcomes that matter to patients, and reports the answer whether the sponsor likes it or not. Marketing, by contrast, is not paid to be boring. Marketing is paid to make a product look memorable, desirable, and just different enough from the competition to win the prescription pad.

The trouble starts when those two worlds stop being neighbors and start sharing a brain. A drug company absolutely can fund rigorous research. In fact, industry money is essential to developing many new medicines. But when the logic of promotion begins to shape the logic of experimentation, science-based medicine gets bent out of shape. The trial may still wear a white coat, still sparkle with randomization and jargon, and still show up in a glossy journal. Yet underneath, the study may be doing less to answer a clinical question than to support a sales story.

That is the real threat. Not industry involvement by itself. Not collaboration with academia by itself. The threat is the replacement of the scientific question, “Does this drug meaningfully help patients?” with the marketing question, “What study design gives this brand the prettiest haircut?”

Why This Matters More Than It Sounds

Clinical trials do not live in a vacuum. Their results shape treatment guidelines, continuing medical education, insurance coverage, hospital formularies, and conversations between doctors and patients. If a trial design exaggerates benefit, hides uncertainty, or buries harm, the distortion does not stay on a spreadsheet. It travels. It becomes a talking point, then a prescribing habit, then a standard of care.

That is why trial design is not a technical footnote. It is the moral center of evidence-based medicine. If the design is tilted, the evidence base tilts with it. By the time the distortion reaches the clinic, it can look very respectable. It may even have a PowerPoint deck.

What Happens When Marketing Starts Steering the Trial

The Comparator Gets Conveniently Weak

One of the easiest ways to make a new drug look good is to compare it against the wrong thing. Instead of testing it against the best current therapy, a trial may use placebo when an active comparison would be more clinically meaningful. Or it may compare the new drug to an older competitor at a weak dose, an awkward schedule, or in a population where the competitor is least likely to shine.

On paper, that still looks like a comparison. In practice, it can be a staged photo. The trial is no longer asking whether the newcomer is better than the care patients actually receive. It is asking whether the sponsor can build a comparison that flatters the newcomer.

This matters because doctors do not prescribe against placebo in everyday life. They prescribe against alternatives. A “positive” trial can therefore be clinically underwhelming while remaining statistically impressive. That is one of marketing’s favorite magic tricks: turn a narrow win into a broad narrative.

The Endpoint Moves Away From the Patient

Another classic move is endpoint selection. The strongest trials measure outcomes patients can feel, function through, or survive: fewer fractures, less pain, fewer heart attacks, longer life, better daily functioning. But those outcomes can take time, cost money, and refuse to cooperate with quarterly sales targets.

So sponsors sometimes lean on surrogate endpoints instead. A lab value improves. A scan looks cleaner. A biomarker drifts in the right direction. Sometimes that is scientifically appropriate; surrogate endpoints can be useful and even necessary in certain settings. But they also create a temptation. A marker can move without delivering the clinical benefit patients actually care about.

When a trial is designed with a marketing mindset, the question quietly shifts from “Will patients do better?” to “What can improve fastest and be packaged most persuasively?” The result is a study that may produce a beautiful graph and a less beautiful answer.

Noninferiority Turns Into a Soft Landing

Noninferiority trials are not inherently shady. In some areas, they are entirely appropriate. If withholding active treatment would be unethical, a placebo-controlled superiority trial may not make sense. But noninferiority designs are delicate instruments. They depend on careful margin selection, a fair comparator, and assumptions that are easy to mangle.

That makes them vulnerable to abuse. A company does not always need to prove its drug is better. Sometimes it only needs to prove the drug is not too much worse, while quietly hoping clinicians will be dazzled by side benefits, convenience, or branding. If the noninferiority margin is too generous, a mediocre product can stroll through the regulatory door looking like a success.

This is where science-based medicine has to stay alert. “Not clearly worse by more than the allowed amount” is not the same thing as “good enough to change practice.” But once the abstract is polished and the conference slides are glowing, those distinctions can get lost faster than a free pen at an industry lunch.

The Population Gets Handpicked

Marketing loves a friendly audience, and trials can be built to find one. Eligibility criteria may exclude patients who are older, sicker, have multiple conditions, take several medications, or are at higher risk for side effects. That can make sense scientifically in early development, but it can also create a carefully manicured population that looks nothing like the real patients who will eventually receive the drug.

If the study group is too healthy, too narrowly selected, or too short-term, the trial may overstate benefit and understate risk. Then the drug reaches everyday practice, meets complicated human beings, and suddenly looks less heroic. Real life has a habit of crashing elegant narratives.

Postapproval Research Becomes Promotional Theater

The most obvious warning sign appears after approval, when a product already has a market and the sponsor wants momentum. This is where so-called seeding trials enter the story. These are studies that look like research from the outside but function more like marketing campaigns from the inside. They can recruit large numbers of community physicians, encourage familiarity with the drug, generate favorable talking points, and normalize prescribing under the banner of scientific participation.

That is not just theoretical hand-wringing. One of the best-known examples is the gabapentin STEPS trial, which has been described in the medical literature as a seeding trial used to promote prescribing, with marketing extensively involved in planning and implementation. When a trial’s hidden purpose is to create loyal prescribers rather than reliable knowledge, science has effectively been rented out as a costume.

Real-World Examples That Keep This Concern Alive

The Gabapentin STEPS Trial

The STEPS trial has become the cautionary tale that refuses to retire, and that is probably a good thing. It showed how a study can carry the appearance of legitimate research while serving a promotional agenda. The lesson is bigger than one drug. It demonstrates the mechanics of how marketing goals can shape trial design, site selection, investigator engagement, and messaging.

In plain English, it is the difference between asking a question and staging an answer.

Study 329 and the Problem of Narrative Overreach

Another often-discussed example is Study 329, the paroxetine trial in adolescent depression. The original publication was influential and presented a favorable picture, but later scrutiny raised serious questions about the conclusions and the reporting of harms. The larger lesson is not limited to one paper or one antidepressant. It is that the abstract, the author list, and the published conclusion can sometimes sound more confident than the underlying data deserve.

That is marketing logic at its most elegant. Do not fabricate data. Just frame them so aggressively that uncertainty gets shoved into the attic.

Postapproval Studies With Tiny Samples and No Useful Comparator

Published analyses of industry-initiated postapproval studies have also raised eyebrows because many of these studies were small, nonrandomized, lacking comparators, or focused on new indications rather than clinically pressing questions. That does not make every postapproval study worthless. Far from it. Some are essential. But a pile of thin, strategically chosen studies can be remarkably good at keeping a product in circulation without truly answering the questions that matter most to patients and clinicians.

In other words, a trial can be scientifically legal, commercially helpful, and still medically undernourished.

How the Literature Gets Polished After the Trial Ends

Bad incentives do not stop at design. They can continue through analysis, authorship, publication, and publicity. Sometimes the sponsor controls or heavily influences the statistical analysis. Sometimes professional writers shape manuscripts while academic names provide prestige. Sometimes unfavorable outcomes are downplayed, secondary analyses are spotlighted, or subgroup findings are dressed up like major discoveries.

Even when journals require disclosure, disclosure alone is not a disinfectant strong enough to sanitize a weak design. A reader still has to ask hard questions. Who wrote the protocol? Who had access to the full dataset? Was the statistical analysis plan available before the results were known? Were outcomes changed along the way? Was the raw data shared, or merely promised with a smile and a locked door?

Recent analyses of influential clinical trials suggest that industry involvement remains common not only in funding but also in authorship and analysis, while meaningful transparency around data and code still lags. That should not trigger cynicism. It should trigger better standards.

How to Read a Trial Without Being Seduced by the Abstract

Start With the Clinical Question

Ask whether the trial addresses a real decision a clinician faces. Is the new drug being compared with the best relevant alternative? Is the patient population one you would actually recognize in clinic? If the study question feels weirdly convenient for the sponsor, trust that instinct and keep digging.

Check What the Trial Counts as Success

If the primary endpoint is a surrogate, ask how confidently that marker predicts real patient benefit. If the endpoint is a composite, ask whether the “win” comes from meaningful events or softer ones that sound impressive but change little in daily life. Composite endpoints can be clinically useful, but they can also function like a group project where one hardworking component does all the work while the others collect credit.

Look for the Missing People

Who was excluded? Frail patients? Older adults? Those with kidney disease, polypharmacy, psychiatric illness, or multiple chronic conditions? A trial built around ideal patients may tell you less about real prescribing than you think.

Follow the Paper Trail

Prospective registration matters. Preplanned outcomes matter. Transparent reporting matters. If the paper reads like a victory speech but the protocol, registry entry, and statistical plan are hard to find, that is not a tiny paperwork issue. That is a reliability issue.

Watch the Language

Marketing loves phrases like “well tolerated,” “encouraging,” “promising,” and “supports use.” Science should be more disciplined. A humble conclusion is often more trustworthy than a triumphant one. When the conclusions sound bigger than the data, your skepticism should stand up and stretch.

What Better Science-Based Medicine Looks Like

The solution is not to exile industry from drug development. That would be unrealistic and, in many cases, counterproductive. The solution is to build walls where they matter and windows where they help.

That means protocols designed around clinically meaningful questions, not messaging opportunities. It means fair comparators, sensible follow-up, and endpoints that matter to patients. It means rigorous conflict-of-interest management, independent scientific review, and clear separation between marketing personnel and trial design decisions. It means registering trials before enrollment, sticking to preplanned analyses, reporting results on time, and making protocols and analysis plans readily available.

It also means journals and academic institutions need backbone. Publication rights should not be strangled by sponsor control. Investigators should have genuine access to data. Independent statisticians should not be decorative accessories. And when a trial is primarily promotional, it should be called what it is instead of being allowed to masquerade as neutral science.

Science-based medicine does not require perfect purity. It requires honest methods, transparent reporting, and enough independence to keep commercial enthusiasm from rewriting the question mid-sentence.

Experience From the Ground: What This Looks Like in Practice

People often imagine bias in clinical research as a dramatic event, like a villain twirling a mustache over a spreadsheet. Real life is usually less cinematic and more slippery. It often starts with something that sounds harmless. A busy physician is invited to participate in a “simple postmarketing study” for a recently approved drug. The paperwork emphasizes education, patient experience, and the value of real-world feedback. The physician is flattered, the coordinator is helpful, and the drug starts appearing more often in the office simply because everyone is now familiar with it. Nothing feels openly corrupt. That is exactly why it works.

Research staff can experience the same slow drift. A coordinator may notice that the case report forms seem obsessed with secondary measures that make for nice promotional copy, while harder clinical outcomes receive less attention or longer follow-up is quietly absent. A statistician may be asked to explore subgroup after subgroup until one of them sparkles. A medical writer may be handed a draft “discussion” section that already sounds like an ad campaign dressed for a conference badge. Each step can be defended in isolation. Together, they create a trial culture that feels less like inquiry and more like choreography.

Patients experience this problem from the most vulnerable position of all. Many people join trials because they believe they are contributing to medical knowledge. They assume the study exists to answer an important question. If the trial is actually structured around market expansion, physician familiarization, or favorable messaging, that assumption has been exploited. The patient still takes on the burden, the uncertainty, and the risk, but the social value of the research may be thinner than promised.

Clinicians reading the literature face a different version of the same challenge. They are busy. Most do not have time to inspect the registry entry, the protocol, the appendix, the supplementary tables, and the conflict disclosures for every paper. So they rely on abstracts, editorials, conference summaries, journal prestige, and word of mouth. That is precisely why promotional design is dangerous. It does not need to fool every methodologist in the country. It only needs to glide smoothly past a tired doctor on a Tuesday afternoon.

Hospital committees and payers encounter yet another layer. They must decide whether a new drug deserves formulary placement, guideline endorsement, or reimbursement preference. If the evidence base is packed with trials that are positive in a technical sense but weak in a practical sense, decision-makers are forced to sort through polished ambiguity. The drug may seem supported by a stack of studies while the actual clinical advantage remains modest, uncertain, or heavily dependent on selective framing.

That is what makes the issue so persistent. The problem is rarely one crooked memo or one outrageous publication. It is the cumulative effect of small design choices, selective emphasis, and institutional politeness around commercial influence. People on the ground often sense that something is off long before they can prove it. A trial feels too easy, too flattering, too eager to declare victory. Science-based medicine depends on taking that feeling seriously and then demanding the documents, methods, and transparency needed to confirm or refute it.

Conclusion

When clinical trials for new drugs are shaped by the marketing division, the danger is not just bias in the abstract. The danger is that medicine begins to confuse persuasion with proof. A beautiful design can answer a hard question. A strategically beautiful design can avoid one.

Science-based medicine survives only when the methods stay tougher than the message. That means trial design must serve patients, not promotion; evidence must be interpretable, not merely impressive; and transparency must be real enough to let outsiders test the claims. If a study is good, it should survive scrutiny. If it only survives applause, it was probably never strong science to begin with.